CTD Quality Consulting

 

Special Course Outline: "cGLP / cGMP: A Basic Primer”
Day 1
Speaker Session Topic
Mukund Chorghade
I
2 Hours

General Introduction and Glossary of Terminology:

  • Regulatory milestones in the progress of a drug from conception to
    commercialization: what is the US drug approval process?
  • The necessity of adhering to stringent specifications of cGLP / cGMP. Specific examples of the consequences of non-compliance will be presented.
  • History of cGLP / cGMP; FDA regulation of pre-clinical testing?
  • What are the differences between cGMP and ISO 9000 regulations?
  • Is cGMP compatible with Total Quality Management?
  • Role of cGMP for clinical R & D: How are safety, quality and uniformity of the product ensured? Key data integrity review points.
Mukund Chorghade
II
2 hours

Organization and management systems:

  • General provisions and salient features of cGLP / cGMP.
  • Organization and management structure: regulatory implications;
    Involvement of personnel in synthesis, analytical, toxicology,
    metabolism and related functions.
  • Construction of organograms, mission statement and quality goals, enumeration of services provided by each department.
  • Requirements for training of staff and documentation of such training: certification of employees, job competency standards, job descriptions, continuing education programs and annual refreshers. Maintenance of staff training records and resumes documenting qualifications and experience of consultants.
  • Writing an effective curriculum vitae; designing flow charts to depict document pedigrees, project management, decision making and documentation, material flow and disposition; product files; storage, archiving and retrieval of data.
  • Study Directors and Quality Control Units: Basic Requirements.
Mukund Chorghade
III
1 hour

Notebooks, logbooks and patents: storage and archiving of data:

  • Maintaining a laboratory notebook--Do's and Don'ts: Patent law and
    regulatory constraints; changes in US law for foreign inventors;
    electronic signatures, batch records and documents, electronic
    submissions.
  • Raw data analysis and reports; traceability of records; rules for
    retention / archiving; documents needed for a patent application.
  • Instrument calibration, use, maintenance and repair log books
Veena Chorghade
IV
2 hours

Standard Operating Procedures and the core elements of cGLP / cGMP:

  • Writing, approval and dissemination of Standard Operating Procedures; training of personnel; change control.
  • Qualification (Installation, operational and performance) and validation of key equipment, apparatus and computer programs.
  • Protocols for identity testing of laboratory reagents; quarantine and QC release; expiration date testing of intermediates and products; reference standards.
  • Impurity profiles, stability of drugs, degradants and metabolites,
    retaining samples.
  • The Barr decision; out of specification results; retesting, resampling
    and remixing; deviations; ICH requirements for analytical procedures.
Day 2
Speaker Session Topic
Veena Chorghade
I
2 hours

Validation:

  • Validation: Bulk Pharmaceutical Chemical vs. Dosage Form.
  • Validation of Solid Dosage Forms: Biobatch relationship, raw materials, manufacturing directions, equipment, granulation / mix analysis, in-process controls, test results, investigations / product failures.
  • Sampling size and process control of mixing; scale of scrutiny.
  • Establishment of limits for cleaning validation.
  • Control of BPC processes: "Control all steps and validate critical ones approach"; prospective, concurrent and retrospective validation.
  • PhRMA guidelines for production, packing and holding of drug
    substances.
Mukund Chorghade
II
2 hours

Technology Transfer Issues:

  • Writing process and technology transfer reports.
  • How to transfer bulk pharmaceutical chemical technology from chemical development to manufacturing.
  • Necessary documentation and preparation for pre- approval inspections.
Mukund Chorghade
III
2 hours

Outsourcing Issues:

  • FDA guidelines for inspection of BPCs.
  • FDA policies on development of enantiomerically pure drugs.
  • Ancilliarisation: Vendor site validation; strategies for sourcing of
    intermediates.
Day 3
Speaker Session Topic
Mukund Chorghade
I
1 hour

Quality Audits and Laboratory Certification Programs:

  • Laboratory certification; internal quality audits of laboratory operations.
  • Conducting a quality audit: A sample questionnaire / audit checklist.
Mukund Chorghade
II
1 hour

The FDA Audit:

  • Dealing with the FDA: Procedures and policies for inspections.
  • Receiving the FDA inspector: have you written an SOP for this?
  • Do's and Don'ts: Conducting yourself during an audit; precautions.
  • The exit interview: FDA 483' s-- Your rights, duties and obligations.
  • Post-approval cGLP / cGMP compliance.
 
III
1.5 hours

Miscellaneous:

  • FDA videos on safety and GMP (Q&A - Discussion time after)
The following sessions (90 minutes each) are optional
 
IV
Regulatory requirements affiliated with filing an IND for New
Chemical / Molecular Entities (NCE's and NME’s); general comments on pharmacology, toxicology etc.
 
V

Additional questions and clarifications.

For more information about CTD Quality consulting, to contact us via email